The perfect mix: recent progress in adjuvant research
- PMID: 17558426
- DOI: 10.1038/nrmicro1681
The perfect mix: recent progress in adjuvant research
Abstract
Developing efficient and safe adjuvants for use in human vaccines remains both a challenge and a necessity. Past approaches have been largely empirical and generally used a single type of adjuvant, such as aluminium salts or emulsions. However, new vaccine targets often require the induction of well-defined cell-mediated responses in addition to antibodies, and thus new immunostimulants are required. Recent advances in basic immunology have elucidated how early innate immune signals can shape subsequent adaptive responses and this, coupled with improvements in biochemical techniques, has led to the design and development of more specific and focused adjuvants. In this Review, I discuss the research that has made it possible for vaccinologists to now be able to choose between a large panel of adjuvants, which potentially can act synergistically, and combine them in formulations that are specifically adapted to each target and to the relevant correlate(s) of protection.
Comment in
-
From 'perfect mix' to 'potion magique'-- regulatory T cells and anti-inflammatory cytokines as adjuvant targets.Nat Rev Microbiol. 2008 Jan;6(1):C1; author reply C2. doi: 10.1038/nrmicro1681-c1. Nat Rev Microbiol. 2008. PMID: 18087776 No abstract available.
Similar articles
-
Modulating vaccine responses with dendritic cells and Toll-like receptors.Immunol Rev. 2004 Jun;199:227-50. doi: 10.1111/j.0105-2896.2004.00144.x. Immunol Rev. 2004. PMID: 15233738 Review.
-
New horizons in adjuvants for vaccine development.Trends Immunol. 2009 Jan;30(1):23-32. doi: 10.1016/j.it.2008.09.006. Epub 2008 Dec 6. Trends Immunol. 2009. PMID: 19059004 Review.
-
Strategies to link innate and adaptive immunity when designing vaccine adjuvants.Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):184-91. doi: 10.1016/j.vetimm.2008.10.298. Epub 2008 Oct 17. Vet Immunol Immunopathol. 2009. PMID: 19042032
-
New adjuvants for human vaccines.Curr Opin Immunol. 2010 Jun;22(3):411-6. doi: 10.1016/j.coi.2010.04.004. Epub 2010 May 11. Curr Opin Immunol. 2010. PMID: 20466528 Review.
-
Immunological foundations to the quest for new vaccine adjuvants.BioDrugs. 2004;18(2):79-93. doi: 10.2165/00063030-200418020-00002. BioDrugs. 2004. PMID: 15046524 Review.
Cited by
-
Tilapia Lake Virus Vaccine Development: A Review on the Recent Advances.Vaccines (Basel). 2023 Jan 23;11(2):251. doi: 10.3390/vaccines11020251. Vaccines (Basel). 2023. PMID: 36851129 Free PMC article. Review.
-
Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.Medicine (Baltimore). 2019 Aug;98(33):e16771. doi: 10.1097/MD.0000000000016771. Medicine (Baltimore). 2019. PMID: 31415377 Free PMC article. Clinical Trial.
-
Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.AAPS J. 2010 Jun;12(2):109-16. doi: 10.1208/s12248-009-9168-2. Epub 2010 Jan 8. AAPS J. 2010. PMID: 20058113 Free PMC article.
-
The Combinations Chitosan-Pam3CSK4 and Chitosan-Monophosphoryl Lipid A: Promising Immune-Enhancing Adjuvants for Anticaries Vaccine PAc.Infect Immun. 2019 Nov 18;87(12):e00651-19. doi: 10.1128/IAI.00651-19. Print 2019 Dec. Infect Immun. 2019. PMID: 31527122 Free PMC article.
-
The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.Front Immunol. 2021 Jun 8;12:677027. doi: 10.3389/fimmu.2021.677027. eCollection 2021. Front Immunol. 2021. PMID: 34168649 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
